Pharmacists’ perspectives on psilocybin in Canada

Elizabeth Sugiarto, Rebecca Leung, Jamie Yuen
{"title":"Pharmacists’ perspectives on psilocybin in Canada","authors":"Elizabeth Sugiarto,&nbsp;Rebecca Leung,&nbsp;Jamie Yuen","doi":"10.1016/j.japhpi.2023.100003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Psilocybin is the main psychoactive component of a naturally occurring psychedelic organism commonly referred to as “magic mushrooms.” Existing literature demonstrates beneficial neurologic effects in treatment-resistant depression, cancer-associated depression and anxiety, and substance use. The evidence base for psilocybin use is on the rise with the U.S. Food and Drug Administration owing to a resurgence in clinical research. As such, pharmacists need to be adequately equipped to navigate questions from consumers and care providers. There is currently no literature describing pharmacists’ perspectives on psilocybin. Evaluating pharmacists’ knowledge, experiences, and opinions about psilocybin may yield beneficial and applicable data to develop educational programs and clinical tools and guide psilocybin policy making.</p></div><div><h3>Objective</h3><p>The objective of this study was to evaluate the interest and opinions of pharmacists on psilocybin as an emerging therapeutic option.</p></div><div><h3>Methods</h3><p>Licensed pharmacists in Canada were invited to participate in an anonymous, online, 44-item survey aimed at evaluating pharmacists’ experiences, knowledge, and attitudes toward psilocybin. Recruitment for the study was done through multiple Canadian pharmacy association newsletters and via LinkedIn.</p></div><div><h3>Results</h3><p>Results showed that 73% of pharmacists lacked formal education about psilocybin. Forty percent of pharmacists had conversations about psilocybin less than once a month whereas 60% of pharmacists have never received questions about psilocybin. Furthermore, pharmacists are not comfortable with their knowledge with making recommendations (75%), monitoring (57%), or recommending doses of psilocybin (64%) to patients.</p></div><div><h3>Conclusion</h3><p>Pharmacists are open to embracing a role in psilocybin therapy and dispensing. Creation of clinical practice guidelines and increased accessibility to education materials are necessary to supplement pharmacists’ knowledge on psilocybin and improve their confidence when advising patients.</p></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"1 2","pages":"Article 100003"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949969023000039/pdfft?md5=4a43d162f6c9858fdb8e155770b69da7&pid=1-s2.0-S2949969023000039-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAPhA Practice Innovations","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949969023000039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Psilocybin is the main psychoactive component of a naturally occurring psychedelic organism commonly referred to as “magic mushrooms.” Existing literature demonstrates beneficial neurologic effects in treatment-resistant depression, cancer-associated depression and anxiety, and substance use. The evidence base for psilocybin use is on the rise with the U.S. Food and Drug Administration owing to a resurgence in clinical research. As such, pharmacists need to be adequately equipped to navigate questions from consumers and care providers. There is currently no literature describing pharmacists’ perspectives on psilocybin. Evaluating pharmacists’ knowledge, experiences, and opinions about psilocybin may yield beneficial and applicable data to develop educational programs and clinical tools and guide psilocybin policy making.

Objective

The objective of this study was to evaluate the interest and opinions of pharmacists on psilocybin as an emerging therapeutic option.

Methods

Licensed pharmacists in Canada were invited to participate in an anonymous, online, 44-item survey aimed at evaluating pharmacists’ experiences, knowledge, and attitudes toward psilocybin. Recruitment for the study was done through multiple Canadian pharmacy association newsletters and via LinkedIn.

Results

Results showed that 73% of pharmacists lacked formal education about psilocybin. Forty percent of pharmacists had conversations about psilocybin less than once a month whereas 60% of pharmacists have never received questions about psilocybin. Furthermore, pharmacists are not comfortable with their knowledge with making recommendations (75%), monitoring (57%), or recommending doses of psilocybin (64%) to patients.

Conclusion

Pharmacists are open to embracing a role in psilocybin therapy and dispensing. Creation of clinical practice guidelines and increased accessibility to education materials are necessary to supplement pharmacists’ knowledge on psilocybin and improve their confidence when advising patients.

药剂师对加拿大迷幻药的看法
背景丝萝西宾是一种天然迷幻生物的主要精神活性成分,通常被称为 "神奇蘑菇"。现有文献表明,它对治疗耐药性抑郁症、癌症相关抑郁症和焦虑症以及药物使用中的神经系统有好处。由于临床研究的复苏,美国食品和药物管理局对使用迷幻蘑菇的证据基础正在增加。因此,药剂师需要做好充分准备,以应对消费者和护理提供者提出的问题。目前还没有文献描述药剂师对迷幻药的看法。评估药剂师对迷幻药的知识、经验和观点可能会产生有益且适用的数据,用于开发教育计划和临床工具,并指导迷幻药政策的制定。方法邀请加拿大的执业药剂师参加一项匿名的在线调查,该调查包含 44 个项目,旨在评估药剂师对迷幻药的经验、知识和态度。这项研究的招募工作是通过多份加拿大药学协会通讯和 LinkedIn 进行的。结果显示,73% 的药剂师缺乏有关迷幻药的正规教育。40%的药剂师每月与西洛赛宾的交谈少于一次,而 60% 的药剂师从未收到过有关西洛赛宾的问题。此外,药剂师对自己在向患者推荐(75%)、监测(57%)或建议西洛赛宾剂量(64%)方面的知识并不满意。有必要制定临床实践指南并增加教育材料的可获取性,以补充药剂师的迷幻剂知识并提高他们为患者提供建议的信心。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信